The MOI of 20 for the second-generation lentiviral vector was selected based on the previous study that showed killing properties of the transduced T cells and clinical benefit in one relapsed ALL patients under the compassionate ground utilizing the same CD19 transgene [17]. Here, CD19 is linked to acute lymphoblastic leukemia.